secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001178913-25-003981
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion receives positive BfArM feedback on Phase 2/3 trial design for SIL204 in pancreatic cancer
--------------------------------------------------------------------------------

- BfArM written Scientific Advice supports proposed Phase 2/3 study design, dosing, patient population, and CMC.
- Phase 2/3 trial initiation for SIL204 planned for Q2 2026, pending regulatory clearance.
- Regulatory submissions expected in Israel by end of Q4 2025 and in Germany during Q1 2026.
- SIL204 targets KRAS-driven locally advanced pancreatic cancer; momentum builds toward clinical launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003981/0001178913-25-003981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003981/zk2534079.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer